



ASX RELEASE
19 April 2013

**General Meeting of Novogen Limited:
Results of General Meeting, Friday 19 April 2013**

Novogen Limited (ASX: NRT) announces that Novogen Shareholders approved all four resolutions put to its general meeting at 1pm today.

The full results of the General Meeting are set out in the tables below:

Vote Details

Resolution	Vote type	Voted	Percentage (%)	Percentage (%) of all securities
1. Approval to raise capital	For	23,738,292	98.23	20.26
	Against	218,718	0.90	0.19
	Open-Usable	208,563	0.86	0.18
	Open-Conditional	2,000	0.01	0.00
	Open Unusable	178,990	N/A	0.15
	Abstain	6,500	N/A	0.01
	Excluded	0	N/A	0.00
	2. Approval to issue shares	For	13,265,319	93.33
Against		737,348	5.19	0.63
Open-Usable		208,563	1.47	0.18
Open-Conditional		2,000	0.01	0.00
Open Unusable		215,740	N/A	0.18
Abstain		606,800	N/A	0.52
Excluded		9,362,293	N/A	7.97

3. Issue shares to Phytose	For	22,659,788	95.99	19.30
	Against	736,348	3.12	0.63
	Open-Usable	208,563	0.88	0.18
	Open-Conditional	2,000	0.01	0.00
	Open Unusable	178,990	N/A	0.15
	Abstain	612,374	N/A	0.52
	Excluded	0	N/A	0.00
	4. Issue convertible notes	For	13,311,245	93.73
Against		659,848	4.65	0.56
Open-Usable		228,563	1.61	0.19
Open-Conditional		2,000	0.01	0.00
Open Unusable		215,740	N/A	0.18
Abstain		618,374	N/A	0.53
Excluded		9,362,293	N/A	7.97

These results are provided in accordance with section 251AA of the *Corporations Act 2001*.

About Novogen Ltd:

Novogen Ltd is a public Australian biotechnology company whose shares trade on both the Australian Stock Exchange (symbol 'NRT') and NASDAQ (symbol 'NVGN'). The Company is based in Sydney, Australia and is focused on the development of a family of novel anti-cancer drugs based on super-benzopyran and 'stealth' drug technologies. The Company's inaugural drug candidate is CS-6.

About CS-6

CS-6 belongs to a new class of drug candidates known (structurally) as super-benzopyrans displaying potent anti-cancer activity and demonstrating increased bio-availability to cancer cells ('stealth' technology). CS-6 shows broad anti-proliferative and cytotoxic activity against human cancer cells, with particular activity against human glioblastoma cells. CS-6 also has been designed deliberately to meet the major known criteria for crossing the blood-brain barrier, and for that reason is being developed as a first-line for the treatment of glioblastoma multiforme, the main form of primary brain cancer.

More information: www.novogen.com